Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 2,266 shares at $74.92 ($171K) on 2026-01-05, disclosed to the SEC on 2026-01-06.
Seasonal sale ($171k) by Executive VP AND CLO — this insider has traded PTCT in January in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $74.92 | 1,123 | $84K | 49.1% |
| 2 | $76.10 | 1,035 | $79K | 46.0% |
| 3 | $76.79 | 108 | $8K | 4.8% |
| Total | $75.55 avg | 2,266 | $171K | 100% |
| Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |